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Abstract
This retrospective observational study of data from the US community oncology setting evaluates real-world
treatment patterns and outcomes for newly diagnosed, elderly patients with acute myeloid leukemia. The
analysis focuses on those patients who did not receive standard induction therapy (“3 D 7”etype regimens).
Background:Many elderly patients with acute myeloid leukemia (AML) are considered ineligible for standard intensive
induction therapy due to performance status and comorbidities. We analyzed treatment patterns and outcomes
among elderly patients newly diagnosed with AML in the US community oncology setting. Methods: A retrospective
observational study was conducted using patient-level data from a network of US community oncology practices
provided by Altos Solutions. Patients aged  60 years, diagnosed with AML between November 2005 and February
2014, with  1 recorded visit and  6 months between diagnosis and data cutoff, were included. Only patients who
received active treatment or best supportive care (BSC) per National Comprehensive Cancer Network (NCCN) AML
Guidelines were analyzed. Results: Of 1139 patients meeting the inclusion criteria, 922 (median age 76 years) received
NCCN-recommended treatments: standard induction (n ¼ 5), low-intensity therapy (n ¼ 425), BSC with hydroxyurea
(HU) (n ¼ 36), or BSC without HU (n ¼ 455). For the low-intensity therapy cohort, median time from diagnosis to
treatment initiation was 17 days; median duration of therapy was 5.1 months. Median overall survival (OS) from
diagnosis in the low-intensity, BSC with HU, and BSC without HU groups was 12.3, 7.0, and 49.4 months, respec-
tively. Median time to next therapy/death was 10.1 months in patients receiving low-intensity therapy. A higher
proportion of patients receiving low-intensity therapy required transfusion or other supportive care versus those
receiving BSC. Conclusions: As expected, OS in patients receiving low-intensity therapy or BSC with HU is poor for
elderly patients with AML. Remarkably, intensive induction strategies are rarely used for older patients in community
oncology practice.
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Treatment Patterns in Elderly Patients With AMLIntroduction practices to characterize real-world treatment patterns among elderly
Acute myeloid leukemia (AML) is the second most common form
of leukemia, accounting for approximately 25%of adult leukemia cases
in theWestern world.1 In 2015, it was projected to represent 1.3% of
new cancer cases and 1.8% of deaths from cancer in the US.2 The
median age at AML diagnosis is 67 years, with 54% of patients diag-
nosed at  65 years; there is a higher incidence of AML in men than
women.2-4 The 5-year relative survival rate (adjusting for normal life
expectancy) is estimated to be approximately 24%.5,6
Complete remission (CR) rates and overall survival (OS) in
elderly patients with AML have improved over time, largely owing
to advances in supportive care and the more widespread use of
azanucleosides.7-11 Recommendations for the management of AML
vary according to age, comorbidities, and performance status.
However, despite speciﬁc guidance for elderly patients with AML,
these patients are less likely to achieve CR and remain relapse-free,
due to a higher frequency of unfavorable cytogenetics, myelodys-
plastic syndromes (MDS), and other adverse biological factors,
which are more commonly found in older patients.12,13 The Na-
tional Comprehensive Cancer Network Clinical Practice Guidelines
in Oncology (NCCN Guidelines) for Acute Myeloid Leukemia,
V1.2015,3 current at the time of this study (referenced with
permission from the NCCN Clinical Practice Guidelines in
Oncology for Acute Myeloid Leukemia V1.2015.  National
Comprehensive Cancer Network, Inc 2015. All rights reserved. To
view the most recent and complete version of the guideline, go
online to NCCN.org), recommend the following options for the
management of AML in elderly patients aged  60 years: investi-
gational therapy, standard induction therapy (with “3 þ 7”etype
regimens), or low-intensity chemotherapy for those patients
considered “ﬁt” (Eastern Cooperative Oncology Group Perfor-
mance Status [ECOG PS] 0-2). For “unﬁt” patients (ECOG PS> 2,
or 0-3 with signiﬁcant comorbidities) the NCCN Guidelines
recommend the use of either investigational therapy, low-intensity
chemotherapy, or best supportive care (BSC); BSC includes man-
agement with hydroxyurea (HU), blood transfusions, growth factors,
and anti-infectives.3 The combined impact of the disease and its
therapy on red blood cell (RBC) counts mandate the use of semi-
regular transfusion support, which imposes a signiﬁcant health cost
during the routine care of patients with AML, irrespective of age.14
A number of studies have investigated real-world health care
resource utilization and treatment outcomes in patients with AML
by using US-based Surveillance, Epidemiology, and End Results
(SEER) program data linked to Medicare claims or administrative
claims data alone.7,8,15-18 These studies support the view that
older patients with AML do badly, with low survival rates (median
1.5-2.0 months when “untreated”) and incursion of high health care
costs (mean $41,594-$96,078 per patient).15-17 Younger patients
with fewer comorbidities are more likely to receive chemotherapy,
whereas older patients have fewer options available to them.16,17
The criteria for deﬁning patients characterized as “elderly”
remains arbitrary; these studies used thresholds ranging from 65 to
75 years of age. In contrast, the NCCN Guidelines deﬁne elderly
patients with AML as those  60 years of age.3
The primary objective of this study was to use aggregated patient-
level clinical data from electronic medical records in US communityClinical Lymphoma, Myeloma & Leukemia November 2016( 60 years) patients newly diagnosed with AML, looking partic-
ularly at the use of the recommended treatment options of the
NCCN Guidelines.3 Secondary objectives included analysis of real-
world outcomes and utilization of supportive therapies (including
blood transfusions and growth factors).
Methods
This retrospective, observational study was conducted using a
dataset provided by Altos Solutions (Los Altos, CA), which includes
oncology-speciﬁc electronic medical records representing 225,000
patients with cancer treated across 150 US community oncology
practices. We studied older patients ( 60 years) who had at least 1
recorded visit and a ﬁrst diagnosis of AML  6 months before data
cutoff (February 24, 2014). The rationale for this selection criterion
was to allow patients to be observed for a minimum of 6 months;
however, deaths occurring within 6 months of ﬁrst diagnosis of
AML were included in the survival analyses. Patients who satisﬁed
these inclusion criteria who began therapy (inclusive of BSC ap-
proaches) during the observational period (November 1, 2005, to
February 24, 2014) were included in the analysis. Patients were
followed from date of initial diagnosis to the earliest date of loss to
follow-up, death, or end of data collection. Patients were excluded
from the study if insufﬁcient data were available to document
baseline characteristics or initial treatment.
For this analysis, patients were allocated to groups based on the
NCCN Guideline recommendations for elderly patients with AML.3
Patients receiving active treatment were grouped according to
whether they had received standard induction therapy (deﬁned as 7
days cytarabine 100-200 mg/m2 plus 3 days of idarubicin 12 mg/m2,
daunorubicin 45-90 mg/m2, or mitoxantrone 12 mg/m2), or low-
intensity therapy (azacitidine, decitabine, or cytarabine at doses
of < 50 mg/m2). Patients receiving other treatments were excluded.
Although some of these excluded patients may have received poten-
tially active investigational agents, which is a recommended treatment
approach in the NCCN Guidelines,3 it was not possible to determine
if this was the case from the dataset; hence, all patients receiving
therapies not explicitly recommended in the NCCN Guidelines were
excluded. Patients who received only supportive therapies (HU,
platelet and RBC transfusions, granulocyte/granulocyte-macrophage
colony-stimulating factors, azole antifungals, erythropoiesis-
stimulating agents, and pain medications), were analyzed within 2
BSC groups: (1) BSC with HU, and (2) BSC without HU.
Treatment regimens were identiﬁed based on the recommenda-
tion of the treating physician during the ﬁrst 28 days after the
initiation of therapy. Treatment discontinuation was deﬁned as the
beginning of a new therapy (not part of the initial treatment
regimen) or at the onset of kinetic failure (> 90 days between
successive cycles or between the last administration of treatment and
the end of follow-up).
Statistical Analyses
We conducted descriptive analyses of retrospective data; no sta-
tistical comparisons were made between study groups. Descriptive
analyses were conducted to quantify patient baseline demographic
and clinical characteristics, treatment patterns, and use of supportive
Figure 1 Disposition of Elderly Patient With AML. Altos Solutions (November 2005-February 2014). aTreatment Included Arsenic
Trioxide, Azacitidine, Bortezomib, Cyclophosphamide, Cytarabine, Decitabine, Dexamethasone, Daunorubicin, Docetaxel,
Doxorubicin, Epirubicin, Idarubicin, Methotrexate, Mitoxantrone, Rituximab, and Tretinoin. bCategory per Earlier NCCN
Guidelines Recommendations.36 cSeven Days Cytarabine 100-200 mg/m2 With 7 Days Idarubicin 12 mg/m2, or 3 Days
Daunorubicin 45-90 mg/m2, or 3 Days Mitoxantrone 12 mg/m2
Abbreviations: AML ¼ acute myeloid leukemia; HU ¼ hydroxyurea; NCCN ¼ National Comprehensive Cancer Network.
Esprit Ma et altherapies. Descriptive statistics for continuous measures included
mean and SD, as well as median and interquartile range (IQR).
Time-to-event measures were estimated using Kaplan-Meier
methodology.
Ethical Approval
The study protocol was reviewed by the New England Institu-
tional Review Board under an exemption status. The study was
conducted in accordance with the applicable regulatory re-
quirements, including patient privacy, and in compliance with
Health Insurance Portability and Accountability Act (HIPAA)
regulations.19 All datasets were supplied as anonymized data.
Results
Elderly AML Patient Disposition
A total of 2200 patients were diagnosed with AML and had at
least 1 more visit in addition to the diagnostic visit (Figure 1). Of
these patients, 1139 (52%) were aged  60 years and had at least 6
months between initial diagnosis and data cutoff. Of the evaluable
cohort, 648 patients (57%) received deﬁnitive therapy (standardinduction or low-intensity therapy) and 491 (43%) received BSC.
Of the 648 patients receiving deﬁnitive therapy, 81 (13%) patients
were excluded from this study because their records showed that
they received treatment before their initial recorded AML diagnosis
(Supplemental Table 1 in the online version); most of these patients
(65/81; 80%) were treated with hypomethylating agents. Among
the 81 patients excluded due to previous therapy, 52 (64%) received
therapy for MDS, 18 (23%) for a cancer diagnosis not otherwise
speciﬁed, 8 (10%) had peripheral blood cytopenias without a
conﬁrmed diagnosis of MDS, and 3 (4%) had an unknown diag-
nosis (data not available). A further 136 (24%) patients who
received active treatment, including 13 patients with a previous
diagnosis of MDS, were excluded, as they received therapy that was
not speciﬁed in the NCCN Guidelines3: most commonly, dexa-
methasone monotherapy (n ¼ 32), high-dose cytarabine mono-
therapy (n ¼ 28), and arsenic trioxide (n ¼ 18; Supplemental
Table 2 in the online version).
Of the remaining 431 patients receiving deﬁnitive therapy
(consistent with current NCCN Guidelines) following their initial
diagnosis of AML, 425 (99%) received low-intensity therapy, andClinical Lymphoma, Myeloma & Leukemia November 2016 - 627
Treatment Patterns in Elderly Patients With AML
628 -5 (1%) received standard induction therapy. Of note, 1 (< 1%)
patient received intermediate-intensity induction with clofarabine,
consistent with the guidelines in place at the time this therapy was
selected.3 Among the 491 patients who received BSC, 36 (7%)
received HU and 455 (93%) received other supportive therapies
without HU. Thus, the ﬁnal study cohort of elderly patients with
AML receiving NCCN-recommended treatment or BSC after initial
diagnosis comprised 922 patients.
Patient Baseline Demographics and Clinical
Characteristics
Overall, the 922 elderly patients with newly diagnosed AML
analyzed in the study cohort had a median age of 73 years (range 60-
96); 55% were men, and 82% were White. Patients had a median
body mass index (BMI) of 27 kg/m2 and 51% were current or
former smokers (Table 1). The median ages of patients receiving
standard and low-intensity therapies were 64 and 76 years, respec-
tively. Of the 36 patients who received BSC with HU (median age
79 years), most (64%) were aged  75 years. Median leukocyte
counts were higher in patients who received BSC with HU,
reﬂecting the need for cytoreduction, compared with patients
receiving low-intensity therapy or BSC without HU (32.0  109/L
vs. 3.5  109/L and 5.5  109/L, respectively; Table 2). Median
follow-up for the overall population was 9 months (9 months for
patients treated with low-intensity therapy, 6 months for patients
receiving BSC with HU, and 12 months for patients receiving BSC
without HU). Most patients (88%) were diagnosed with AML < 3
months before initiation of induction therapy or BSC with HU.
Overall, 15% of patients had MDS before developing AML but
were treatment-naïve and therefore were included in this analysis.
Because of the limited number of elderly patients treated with
standard therapy in our study cohort, subsequent analyses focused
on the groups receiving treatment with low-intensity therapy and
BSC with or without HU.
Treatment Patterns
Six patients in our study cohort were treated with standard in-
duction chemotherapy; none of these was older than 75 years. Most
treated patients received low-intensity therapies (n ¼ 425, 99%). Of
these patients, 216 (51%) received decitabine at a median dose of
19 mg/m2 (IQR 19-20), 203 (48%) received azacitidine at a median
dose of 73 mg/m2 (IQR 72-75), and 6 (1%) received low-dose
cytarabine at a median dose of 11 mg/m2 (IQR 10-12). Median
time from diagnosis to initial treatment for the low-intensity cohort
was 17 days (IQR 5-89), and median duration of therapy was 5.1
months (IQR 2.7-15.4). Of the 425 patients who received low-
intensity therapy, a total of 166 patients (39%) discontinued
initial therapy, of whom 110 (26%) were switched to another
therapy. Most of these patients continued on a low-intensity ther-
apy: 43 (39%) on azacitidine, 51 (46%) on decitabine, and 5 (5%)
on cytarabine; the other 11 (10%) received different combination
therapies. The other 259 patients receiving low-intensity therapy
either died (69%) or were lost to follow-up (31%).
Outcomes
In the low-intensity therapy, BSC with HU, and BSC without
HU groups, 294 (69%), 30 (83%), and 171 (38%) patients,Clinical Lymphoma, Myeloma & Leukemia November 2016respectively, died during the observation period. Median OS from
diagnosis was 12.3 months for the low-intensity therapy group and
7.0 months for the BSC with HU group (Figure 2A). Median OS
from treatment initiation was 8.6 months for the low-intensity
therapy group and 4.8 months for the BSC with HU group
(Figure 2B). In the BSC without HU group, median OS from
diagnosis was 49.4 months (Figure 2A). We investigated possible
explanations for this prolonged OS in the BSC without HU group
by comparing baseline characteristics in patients who were still alive
12 months after AML diagnosis compared with those who had died,
as this was the point at which the OS curves appeared to separate
(Figure 2). Patients who were still alive after 12 months were younger
and had higher hemoglobin levels (Table 3). To further investigate
this observation, we carried out an analysis of prognostic factors for
this cohort, which conﬁrmed that older age and low hemoglobin
were statistically signiﬁcant predicting factors for 12-month mortality
following AML diagnosis (Table 4). Median time to next therapy or
death in the low-intensity therapy and BSC with HU groups were
10.1 and 7.0 months, respectively. Patients in the BSC without HU
group did not receive additional treatment approaches.
Blood Transfusions and Supportive Care
Supportive care, including transfusion support, for patients
treated with low-intensity therapy or BSC with/without HU is
summarized in Supplemental Table 3 in the online version. Within
a year of diagnosis, 22% of patients in the low-intensity group, 17%
in the BSC with HU group, and 11% in the BSC without HU
group received  1 transfusion. Patients treated with low-intensity
therapy received a mean of 3.6 transfusions per month over the
period between ﬁrst and last transfusion (mean duration 4.1
months); patients who received BSC with/without HU received 8.2
and 6.8 transfusions per month, respectively, between ﬁrst and last
transfusion (mean duration 1.1 and 3.5 months).
Overall, 79% of patients treated with low-intensity therapy
received analgesia compared with 64% for patients receiving BSC
with HU and 58% for patients receiving BSC without HU. In
addition, 41% of patients in the low-intensity group, 11% in the
BSC with HU group, and 10% in the BSC without HU group
received granulocyte colony-stimulating factors or granulocyte-
macrophage colony-stimulating factors.
Discussion
This study of newly diagnosed, previously untreated, elderly
patients with AML characterizes real-world treatment patterns and
outcomes in US community practices, as well as use of transfusions
and other supportive care. Remarkably, our study highlights that
despite the availability of low-intensity therapies for elderly
patients ( 60 years of age), 43% of patients in this study did not
receive any deﬁnitive antileukemic therapy. Of those patients
who received an active treatment, 24% received therapies not
explicitly recommended by the NCCN Guidelines.3 This may
reﬂect changes in recommendations over the study period (although
recommendations have remained fairly consistent during the period
for this analysis), a lack of conﬁdence among physicians about the
efﬁcacy of recommended treatment options, or the prescribing
physician’s personal preference/experience with a particular treat-
ment regimen, as well as potential reimbursement factors. The
Table 1 Baseline Clinical Characteristics and Demographics of Elderly Patients With AML
Overall Population,
n [ 922a
Standard Induction
Therapy,
n [ 5
Low-Intensity
Therapy,
n [ 425
BSC With HU,
n [ 36
BSC Without HU,
n [ 455
Women, n (%) 411 (45) 2 (40) 176 (41) 16 (44) 217 (47)
Age (years), mean  SD 73.1  8 65.2  3 75.3  7 77.4  9 70.8  8
Median 73 64 76 79 69
Age group (years), n (%)
60-69 352 (38) 4 (80) 97 (23) 8 (22) 243 (53)
70-79 345 (37) 1 (20) 200 (47) 12 (33) 132 (29)
 80 225 (24) 0 128 (30) 16 (44) 80 (18)
Race, n (%) n ¼ 663a n ¼ 4 n ¼ 323 n ¼ 20 n ¼ 315
White 544 (82) 2 (50) 264 (82) 17 (85) 260 (83)
African American 32 (5) 1 (25) 11 (3) 0 20 (6)
Asian 8 (1) 0 5 (2) 1 (5) 2 (< 1)
Other 79 (12) 1 (25) 43 (13) 2 (10) 33 (10)
US region, n (%)b
South 369 (40) 2 (40) 147 (35) 14 (39) 205 (45)
Northeast 242 (26) 1 (20) 124 (29) 13 (36) 104 (23)
Midwest 151 (16) 1 (20) 69 (16) 6 (17) 75 (16)
West 153 (17) 1 (20) 79 (19) 3 (8) 70 (15)
Puerto Rico/Virgin Islands 5 (< 1) 0 5 (1) 0 0
Unknown 2 (< 1) 0 1 (< 1) 0 1 (< 1)
BMI, kg/m2
Mean  SD 28  6 25  3 28  6 27  5 28  6
Median 27 23 27 27 27
n (%) 629 (68) 5 (100) 339 (80) 24 (67) 260 (57)
Smokers (at any time), n (%) 471 (51) 4 (80) 240 (57) 20 (56) 206 (45)
Year of ﬁrst AML diagnosis, n (%)
 2010 301 (33) 2 (40) 116 (27) 11 (31) 172 (38)
2011 187 (20) 0 101 (24) 7 (19) 79 (17)
2012 259 (28) 0 133 (31) 11 (31) 114 (25)
2013 175 (19) 3 (60) 75 (18) 7 (19) 90 (20)
Time (months) between ﬁrst AML diagnosis
and ﬁrst AML treatment, mean  SD
4.1  11.4 9.5  20.0 4.0  11.3 2.1  5.5 n/a
Median 0.6 0.3 0.6 0.5 n/a
Distribution, n (%)
< 3 months 815 (88) 4 (80) 319 (75) 31 (86) n/a
 3 months 107 (12) 1 (20) 106 (25) 5 (14) n/a
History of MDS diagnosis, n (%) 137 (15) 1 (20) 45 (11) 2 (6) 20 (4)
Observation period (months), mean  SDc 17.0  24 32.7  61 13.1  15 7.9  8 21.3  29
Median 9 10 9 6 12
Abbreviations: AML ¼ acute myeloid leukemia; BMI ¼ body mass index; BSC ¼ best supportive care; HU ¼ hydroxyurea; MDS ¼ myelodysplastic syndrome; n/a ¼ not applicable.
aOne 82-year-old, White, man from the US South received intermediate induction therapy with clofarabine; data by regimen are therefore not shown for intermediate induction therapy.
bUS states included in each region: Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin; Northeast: Connecticut, Maine,
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana,
Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia; West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico,
Oregon, Utah, Washington, Wyoming.
cObservation period is deﬁned as the number of months between the ﬁrst administration of recent AML therapy and the earliest of loss of follow-up, or the date of data collection.
Esprit Ma et alanalyses presented here contribute to the body of literature on
treatment patterns in AML, in which most analyses of real-world
data have assessed treatment in a narrower cohort of patients,
typically  65 or  75 years of age, which is inconsistent with thedeﬁnition of elderly patients ( 60 years) presented by the NCCN
Guidelines.3
In the current study, we found 57% of patients received some
form of active treatment (recommended or nonrecommended)Clinical Lymphoma, Myeloma & Leukemia November 2016 - 629
Table 2 Baseline Laboratory Results of Elderly Patients With AML
Overall Population,
n [ 922a
Standard Induction
Therapy,
n [ 5
Low-Intensity
Therapy,
n [ 425
BSC With HU,
n [ 36
BSC Without HU,
n [ 455
Leukocyte count,  109/L n ¼ 585 n ¼ 5 n ¼ 304 n ¼ 23 n ¼ 253
Mean  SD 11.1  20.9 4.4  1.6 10.3  19.7 41.7  38.1 9.5  18.1
Median 4.7 4.3 3.5 32.0 5.5
Distribution, n (%)
< 6.7 376 (64) 4 (80) 211 (69) 3 (13) 158 (62)
6.7-10 81 (14) 1 (20) 26 (9) 1 (4) 53 (21)
10-15 37 (6) 0 16 (5) 3 (13) 18 (7)
> 15 91 (16) 0 51 (17) 16 (70) 24 (9)
Lymphocytes, K/mL n ¼ 476 n ¼ 5 n ¼ 241 n ¼ 17 n ¼ 213
Mean  SD 3.2  6.8 5.2  7.7 3.2  5.6 5.5  9.7 3.0  7.7
Median 1.5 2.2 1.4 3.0 1.7
Hemoglobin, g/dL n ¼ 589 n ¼ 5 n ¼ 305 n ¼ 24 n ¼ 255
Mean  SD 10.4  2.5 9.7  2.2 9.8  1.7 9.8  1.6 11.3  3.2
Median 10.1 10.7 9.7 9.3 10.6
Distribution, n (%)b
< 9 g/dL 160 (27) 1 (20) 101 (33) 9 (38) 49 (19)
9-12 g/dL 304 (52) 4 (80) 169 (55) 12 (50) 119 (47)
> 12 g/dL 125 (21) 0 35 (11) 3 (13) 87 (34)
Albumin (g/dL), mean  SD n ¼ 365 n ¼ 4 n ¼ 212 n ¼ 11 n ¼ 138
Mean  SD 3.8  0.6 4.0  0.7 3.7  0.5 4.1  0.5 3.9  0.6
Median 3.8 4.2 3.8 4.0 3.9
Distribution, n (%)
> 3.5 g/dL 254 (70) 3 (75) 142 (67) 11 (100) 98 (71)
 3.5 g/dL 111 (30) 1 (25) 70 (33) 0 40 (29)
Total bilirubin, mg/dL n ¼ 313 n ¼ 4 n ¼ 179 n ¼ 12 n ¼ 118
Mean  SD 0.7  0.5 0.4  0.1 0.8  0.6 0.6  0.4 0.6  0.4
Median 0.6 0.4 0.6 0.5 0.6
Distribution, n (%)
< ULN 282 (90) 4 (100) 158 (88) 11 (92) 109 (92)
 ULN 31 (10) 0 21 (12) 1 (8) 9 (8)
Liver function, n (%) n ¼ 335 n ¼ 3 n ¼ 190 n ¼ 11 n ¼ 131
ALT and AST < 2.5 ULN 329 (98) 3 (100) 186 (98) 11 (100) 129 (98)
ALT or AST  2.5 ULN 6 (2) 0 4 (2) 0 2 (2)
Creatinine serum, mg/dL n ¼ 368 n ¼ 4 n ¼ 209 n ¼ 13 n ¼ 142
Mean  SD 1.1  0.5 0.8  0.3 1.0  0.4 1.3  0.6 1.1  0.6
Median 1.0 0.9 1.0 1.1 1.0
Abbreviations: ALT ¼ alanine aminotransferase; AML ¼ acute myeloid leukemia; AST ¼ aspartate aminotransferase; BSC ¼ best supportive care; HU ¼ hydroxyurea; ULN ¼ upper limit of normal.
aOne 82-year-old, White, man from the US South received intermediate induction therapy with clofarabine.
bPercentages may not equal 100% due to rounding.
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630 -and 43% received BSC. This treatment rate is slightly higher than
that reported in some previous SEER studies, which identiﬁed the
use of chemotherapy in 30% to 43% of cases; however, these
studies included older patients with AML ( 65 years).15-17
NCCN Guidelines recommend a clinical trial, standard induc-
tion chemotherapy, or low-intensity therapy as treatment options
for those eligible for active treatment.3 Hypomethylating agents,
such as decitabine or azacitidine (which has recently had its
indication extended in Europe to include adult patients with
AML aged  65 years who are not eligible for hematopoietic stemClinical Lymphoma, Myeloma & Leukemia November 2016cell transplantation20), which are classiﬁed as low-intensity ther-
apies, have proved more effective than BSC alone in some
studies,21,22 yet have shown little or no beneﬁt in others.23-26 In
our study, most elderly patients with AML in the US community
practice setting received low-intensity therapy or BSC. It there-
fore appears that patients treated in the community setting are
more likely to receive more conservative treatment; this may
reﬂect a lack of infrastructure and facilities to provide more
intensive induction therapy, which is often available only at ter-
tiary centers.
Figure 2 Overall Survival From (A) AML Diagnosis, (B) First AML Treatment
Abbreviations: AML ¼ acute myeloid leukemia; BSC ¼ best supportive care; HU ¼ hydroxyurea; NR ¼ not reached.
Esprit Ma et al
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Table 3 Baseline Characteristics of Patients in the BSC Without HU Cohort, Stratiﬁed by Patients Who Died Within 12 Months of First
AML Diagnosis and Those Who Did Not
Patients Who Died Within 12 Months
of First AML Diagnosis n [ 146
Patients Who Were Alive After 12 Months
of AML Diagnosis n [ 309
Women, n (%) 71 (49) 146 (47)
Age (years), mean  SD 74.1  9 69.3  7
Median 73 68
Age group (years), n (%)
60-64 27 (18) 102 (33)
65-69 30 (21) 84 (27)
70-74 21 (14) 50 (16)
75-79 20 (14) 41 (13)
80-84 25 (17) 19 (6)
 85 23 (16) 13 (4)
Race, n (%)
White 68 (47) 192 (62)
African American 6 (4) 14 (5)
Asian 0 2 (< 1)
Other 7 (5) 26 (8)
Unknown 65 (45) 75 (24)
Region of the US, n (%)a
South 64 (44) 141 (46)
Northeast 42 (29) 62 (20)
Midwest 22 (15) 53 (17)
West 17 (12) 53 (17)
Unknown 1 (< 1) 0
Year of ﬁrst AML diagnosis, n (%)
< 2010 32 (22) 58 (19)
2010 19 (13) 32 (10)
2011 20 (14) 59 (19)
2012 38 (26) 76 (25)
2013 29 (20) 61 (20)
History of MDS diagnosis, n (%) 6 (4) 5 (2)
Hemoglobin distribution, n (%)
< 9 g/dL 29 (20) 20 (6)
9-12 g/dL 52 (36) 67 (22)
> 12 g/dL 7 (5) 80 (26)
Unknown 58 (40) 142 (46)
Leukocyte count distribution,  109/L, n (%)
< 6.7 60 (41) 98 (32)
6.7-10 9 (6) 44 (14)
> 10-15 8 (5) 10 (3)
> 15 10 (7) 14 (5)
Unknown 59 (40) 143 (46)
Albumin distribution, n (%)
> 2.5 g/dL 2 (1) 2 (< 1)
 2.5 g/dL 41 (28) 93 (30)
Unknown 103 (71) 214 (69)
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Table 4 Factors Predicting for Death Within the First 12 Months Following AML Diagnosis
HRa (95% CI) P
Age vs. reference “60-65 years old”
65-69 years old 1.40 (0.74-2.65) .294
70-74 years old 1.72 (0.83-3.58) .146
75-79 years old 1.92 (0.91-4.05) .085
80-84 years old 3.47 (1.56-7.74) .002
 85 years old 4.12 (1.69-10.04) .002
Year of ﬁrst AML diagnosis vs. reference “before 2010”
2010 1.00 (0.45-2.22) .996
2011 0.83 (0.40-1.71) .614
2012 0.99 (0.52-1.90) .978
2013 1.17 (0.57-2.38) .667
Women 0.99 (0.63-1.56) .973
Race vs. reference “Other/Unknown”
White 0.66 (0.41-1.05) .077
US region vs. reference “South/Unknown”
Northeast 1.35 (0.74-2.45) .327
Midwest 0.95 (0.49-1.84) .874
West 0.66 (0.33-1.30) .230
History of MDS diagnosis 3.28 (0.71-15.09) .126
Hemoglobin vs. reference “ 12 g/dL”
< 9 g/dL 11.22 (3.96-31.81) <.001
9-12 g/dL 6.01 (2.38-15.15) <.001
Unknown 2.63 (0.21-32.92) .453
Leukocytes vs. reference “< 6.7  109/L”
6.7-10 0.48 (0.18-1.28) .145
10-15 1.39 (0.43-4.48) .580
> 15 0.78 (0.28-2.17) .640
Unknown 1.35 (0.11-15.88) .812
Albumin vs. reference “ 2.5 g/dL”
> 2.5 g/dL 0.78 (0.10-6.23) .812
Unknown 3.75 (0.21-66.67) .368
Creatinine serum vs. reference “> 1.3 mg/dL”
 1.3 mg/dL 0.91 (0.32-2.55) .853
Unknown 0.23 (0.03-1.71) .152
Abbreviations: AML ¼ acute myeloid leukemia; CI ¼ conﬁdence interval; HR ¼ hazard ratio.
aHazard ratios (HR) were estimated using a logistic regression model.
Table 3 Continued
Patients Who Died Within 12 Months
of First AML Diagnosis n [ 146
Patients Who Were Alive After 12 Months
of AML Diagnosis n [ 309
Creatinine serum distribution, n (%)
> 1.3 mg/dL 35 (24) 81 (26)
 1.3 mg/dL 11 (8) 15 (5)
Unknown 100 (68) 213 (69)
Abbreviation: AML ¼ acute myeloid leukemia.
aUS states included in each region: Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota,Wisconsin; Northeast: Connecticut, Maine,
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont; South: Alabama,Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana,
Maryland, Mississippi, North Carolina, Oklahoma, South Carolina,Tennessee, Texas, Virginia, West Virginia; West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico,
Oregon, Utah,Washington, Wyoming.
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634 -The overall proportion of patients in our analysis with a pre-
vious history of MDS (15%; n ¼ 137) was comparable to a
previous SEER report (17.5%).17 However, this may be an un-
derestimate, because recent clinical trials suggest that as many as
32% of patients with AML ( 65 years old) have antecedent
MDS, following blinded central review of peripheral blood, bone
marrow, and cytogenetics.27 It is likely that the true incidence of
antecedent MDS in our cohort is underestimated due to absence
of historical blood counts and expert pathology review. Of note,
71 patients with a previous diagnosis of MDS in our analysis
received treatment before their AML diagnosis (and were there-
fore excluded); baseline demographics and clinical characteristics
for this group were largely similar to the overall analysis cohort
(data not shown).
Several SEER studies have assessed health care resource utiliza-
tion and costs in elderly patients with AML, with most costs
attributed to inpatient care.15,16 The rates of transfusions and
supportive care from the present study are consistent with the
relatively high health care utilization and costs among patients with
AML that have been observed in other studies. In the year following
an initial AML diagnosis, 22% of patients who received low-
intensity therapy, 17% of patients who received BSC with HU,
and 11% of patients who received BSC without HU required  1
blood transfusion. Somewhat surprisingly, no HU-treated patients
received an RBC transfusion, which is inconsistent with what is
observed in standard clinical care. One possible explanation for this
is that those patients who received HU and required an RBC
transfusion in our study cohort were captured in the “transfusion of
unknown type” category. Patients who received low-intensity
therapy also required supportive care, with 70% taking pain
medication and 41% receiving granulocyte/granulocyte-macrophage
colony-stimulating factors; these rates were 64% and 11%, respec-
tively, in patients receiving BSC with HU, and 58% and 10%,
respectively, in patients receiving BSC without HU.
In the absence of detailed information on AML subtyping, risk
status, and prognosis (eg, symptoms, cytogenetics, blast percentages,
comorbidities, complications), it is difﬁcult to interpret the OS data.
However, the median survival times from treatment initiation re-
ported in the low-intensity and BSC with HU groups (8.6 and 4.8
months, respectively) are in line with reports from other population-
based studies of older patients with AML.7,17,28 The remarkably long
median OS observed in the BSC without HU group (49.4 months)
was surprising; closer inspection of the OS curves suggested that
patients in the BSC without HU cohort started to do better than the
other cohorts approximately 12 months after diagnosis. Further
analysis of the baseline characteristics of this cohort conﬁrmed that
these patients were younger and had higher hemoglobin levels; these
factors were statistically signiﬁcant predictors for 12-month mortality
following AML diagnosis. These data suggest that these patients were
more likely than those in the other groups to have more biologically
indolent disease. Alternatively, there is a subset of older patients with
AML with smoldering disease who enjoy long progression/
complication-free survival, but these patients are extremely rare.
Many of these patients have M2 FAB subtype disease and present
with a signiﬁcantly better performance status, lower white blood cell
count, lower circulating blast count, and lower bone marrow inﬁl-
tration than AML cases with more rapid progression.29,30 A keyClinical Lymphoma, Myeloma & Leukemia November 2016limitation of this study is that more detailed rationales for treatment
decisions (eg, details of symptoms, frailty status, life-threatening
complications, infections/sepsis) were not available.
Findings from our study may not be generalizable to the broader
US population of elderly patients newly diagnosed with AML
(20,830 new cases in 2015),31 given the limited sample size available
from the data source. In addition, we encountered missing data for
some health outcome variables, such as response, progression-free
survival, complications, and hospitalizations, because they were not
necessary for reimbursement. Furthermore, mechanisms for
capturing and documenting clinical data differ across oncology
clinics and between oncologists. Data were not available to support
analyses of clinical characteristics (such as cytogenetics and AML
subtyping) or clinical outcomes (such as response and tumor pro-
gression). Further studies supplemented with additional data sources,
including chart extraction to evaluate response, will be necessary to
provide a more comprehensive picture of real-world treatment pat-
terns and outcomes in elderly patients newly diagnosed with AML.
Conclusion
In this study, we conﬁrm the trend for community practitioners to
favor more palliative approaches in the management of AML.
Remarkably, of the entire cohort, only 5 patients (0.5%) received
standard induction chemotherapy. The literature supports the notion
that intensive therapy reduces early mortality, increases remission
rates, and improves OS for patients with AML up to the age of 80
years, when compared with palliative therapy.32 Although rates of
remission with standard approaches are low for older patients, it also
should be noted that for patients with a good AML prognosis, rates
of CR following induction therapy are comparable for older versus
younger patients.33 Although the probability of older patients
entering CR with standard induction chemotherapy is low, the value
of attaining this response cannot be understated. Achievement of CR
reduces the need for toxic therapies, alleviates dangerous cytopenias
to keep patients out of hospital, and, for a select few, provides a
platform for potentially curative therapy in the form of stem cell
transplantation. CR therefore is an important milestone for
improving survival. When evaluating older patients, we would
encourage clinicians to seek compelling reasons not to give therapy,
beyond a general sense of skepticism that induction therapy is “too
toxic.” In this regard, the use of comorbidity scoring systems may
prove useful when selecting older patients for induction therapy in a
more evidence-based way.34 In addition, advances in supportive care
have enhanced our ability to protect patients from complications
ensuing from bone marrow aplasia, following intensive therapy.35
Clinical Practice Points
 What is already known about this subject?
Many patients with AML are not considered eligible for
standard intensive induction therapy due to age, poor prog-
nostic characteristics, or disease that is resistant to standard
chemotherapy. To date, alternative treatment options for these
patients are limited. NCCN Guidelines recommend a clinical
trial, standard induction therapy, or low-intensity chemo-
therapy for elderly patients with AML considered “ﬁt,” and a
clinical trial, low-intensity chemotherapy, or BSC for elderly
patients with AML considered “unﬁt.”
Esprit Ma et al What are the new ﬁndings?
This study highlighted that, despite the availability of
chemotherapy for elderly patients with AML (including low-
intensity therapy), many receive only BSC. The study
particularly highlights the low use of standard- and
intermediate-intensity induction regimens in community
oncology practice. How might it affect clinical practice in the foreseeable future?
These real-world data highlight the need for effective alter-
native treatments for elderly patients with newly diagnosed
AML. New therapies suitable for this patient population
would provide additional management options, particularly
for those considered ineligible for standard therapy.Acknowledgment
The authors acknowledge the writing support of Helen Johns and
Catherine Crookes of FireKite, an Ashﬁeld company, part of UDG
Healthcare plc, in the development of this manuscript, which was
funded by Millennium Pharmaceuticals, Inc. and complied with
Good Publication Practice 3 ethical guidelines (Battisti et al, Ann
Intern Med 2015;163:461-4). This analysis was funded by
Millennium Pharmaceuticals, Inc. The research and writing support
was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, a
wholly owned subsidiary of Takeda Pharmaceutical Company
Limited. Employees of Millennium Pharmaceuticals, Inc., and em-
ployees of Analysis Group, Inc., which received research funding from
Millennium Pharmaceuticals, Inc., were involved in study design; in
the collection, analysis and interpretation of data; in the writing of the
report; and in the decision to submit the article for publication. All
authors had access to the study data and the corresponding author
made the ﬁnal decision to submit the manuscript for publication.
Disclosure
Esprit Ma and Vijayveer Bonthapally are former employees of
Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly
owned subsidiary of Takeda Pharmaceutical Company Limited.
Bruce Dezube is an employee of Millennium Pharmaceuticals, Inc.,
Cambridge, MA, a wholly owned subsidiary of Takeda Pharma-
ceutical Company Limited, and has stock ownership or options for
Takeda Pharmaceutical Company Limited. Anita Chawla, Patrick
Lefebvre, Marie-Hélène Lafeuille, Jonathan Fortier, Bruno Emond,
and Mei Sheng Duh are employees of Analysis Group, Inc., which
received research funding from Millennium Pharmaceuticals, Inc. to
conduct this study. Ronan Swords has no conﬂicts to declare.Supplemental Data
Supplemental tables accompanying this article can be found in
the online version at http://dx.doi.org/10.1016/j.clml.2016.08.006.References
1. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology.
Cancer 2006; 107:2099-107.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:
5-29.3. Acute Myeloid Leukemia. National Comprehensive Cancer Network Clinical
Practice Guidelines in OncologyeV1.2015, National Comprehensive Cancer
Network [Web site]. Available at: http://www.nccn.org/professionals/physician_
gls/PDF/aml.pdf. Accessed: March 3, 2016.
4. Sekeres MA. Treatment of older adults with acute myeloid leukemia: state of the
art and current perspectives. Haematologica 2008; 93:1769-72.
5. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship
statistics, 2014. CA Cancer J Clin 2014; 64:252-71.
6. Howlander N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review,
1975-2011, National Cancer Institute, Bethesda, MD. Based on November 2013
SEER data submission, posted to the SEER Web site, April 2014. Available at:
http://seer.cancer.gov/csr/1975_2012/. Accessed: March 18, 2016.
7. Shah BK, Ghimire KB. Improved survival among older acute myeloid leukemia
patients—a population-based study. Acta Oncol 2014; 53:935-8.
8. Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients
with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer
2013; 119:2720-7.
9. Vasu S, Blum W. Emerging immunotherapies in older adults with acute myeloid
leukemia. Curr Opin Hematol 2013; 20:107-14.
10. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as
treatment for older patients with acute myeloid leukemia considered unsuitable for
intensive chemotherapy. J Clin Oncol 2010; 28:2389-95.
11. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with
acute myeloblastic leukemia in the early 21st century. Haematologica 2008; 93:
594-600.
12. Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol 2012;
96:186-93.
13. Klepin HD, Balducci L. Acute myelogenous leukemia in older adults. Oncologist
2009; 14:222-32.
14. Mahmoud D, Skikne B, Kucmin-Bemelmans I, Alleman C, Hensen M. Overall
economic burden of total treatment costs in acute myeloid leukemia throughout
the course of the disease. Blood (ASH Annual Meeting Abstracts) 2012; 120:
3614.
15. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs
of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162:
1597-603.
16. Meyers J, Yu Y, Kaye JA, Davis KL. Medicare fee-for-service enrollees with pri-
mary acute myeloid leukemia: an analysis of treatment patterns, survival, and
healthcare resource utilization and costs. Appl Health Econ Health Policy 2013; 11:
275-86.
17. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a
population-based study. Haematologica 2012; 97:1916-24.
18. Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ. Survival and hospital-
ization among patients with acute myeloid leukemia treated with azacitidine or
decitabine in a large managed care population: a real-world, retrospective, claims-
based, comparative analysis. Exp Hematol Oncol 2014; 3:10.
19. US Department of Health and Human Services. Code of federal regulations. Title
45. Public Welfare CFR 2005. Available at: http://www.nih.gov/institutes-nih/nih-
ofﬁce-director/ofﬁce-communications-public-liaison/freedom-information-act-
ofﬁce/code-federal-regulations. Accessed: December 14, 2015.
20. Celgene Press Release. Celgene’s VIDAZA (Azacitidine for Injection) Approved by the
European Commission as New Treatment for Elderly Patients with Acute Myeloid
Leukaemia 2015, Available at: http://ir.celgene.com/releasedetail.cfm?releaseid=939462.
Accessed: December 14, 2015.
21. Cashen AF, Schiller GJ, O’Donnell MR, Dipersio JF. Multicenter, phase II study
of decitabine for the ﬁrst-line treatment of older patients with acute myeloid
leukemia. J Clin Oncol 2010; 28:556-61.
22. Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of
decitabine as ﬁrst-line treatment for older patients with acute myeloid
leukemia judged unﬁt for induction chemotherapy. Haematologica 2012; 97:
393-401.
23. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efﬁcacy of azacitidine compared
with that of conventional care regimens in the treatment of higher-risk myelo-
dysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol
2009; 10:223-32.
24. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall
survival compared with conventional care regimens in elderly patients
with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28:
562-9.
25. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized,
open-label, phase III trial of decitabine versus patient choice, with physician
advice, of either supportive care or low-dose cytarabine for the treatment of older
patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30:
2670-7.
26. van der Helm LH, Scheepers ER, Veeger NJ, et al. Azacitidine might be bene-
ﬁcial in a subgroup of older AML patients compared to intensive chemotherapy:
a single centre retrospective study of 227 consecutive patients. J Hematol Oncol
2013; 6:29.
27. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azaci-
tidine vs conventional care regimens in older patients with newly diagnosed AML
with >30% blasts. Blood 2015; 126:291-9.
28. Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C.
Big data analysis of treatment patterns and outcomes among elderly acute
myeloid leukemia patients in the United States. Ann Hematol 2015; 94:
1127-38.Clinical Lymphoma, Myeloma & Leukemia November 2016 - 635
Treatment Patterns in Elderly Patients With AML
636 -29. Baudard M, Legrand O, Marie JP, Zittoun R. Smoldering acute myelogenous
leukemia in the elderly. Leuk Lymphoma 1999; 34:561-7.
30. Marisavljevic D, Markovic O, Zivkovic R. An unusual case of smoldering AML
with prolonged indolent clinical course and spontaneous remission in the terminal
phase. Med Oncol 2009; 26:476-9.
31. SEER Stat Fact Sheets. Acute Myeloid Leukemia (AML) 2015. Available at: http://
seer.cancer.gov/statfacts/html/amyl.html. Accessed: December 14, 2015.
32. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real
world data on decision to treat and outcomes from the Swedish Acute Leukemia
Registry. Blood 2009; 113:4179-87.Clinical Lymphoma, Myeloma & Leukemia November 201633. Yanada M, Ohtake S, Miyawaki S, et al. The demarcation between younger and
older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies.
Cancer 2013; 119:3326-33.
34. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-
speciﬁc comorbidity index: a new tool for risk assessment before allogeneic HCT.
Blood 2005; 106:2912-9.
35. Showel MM, Levis M. Advances in treating acute myeloid leukemia. F1000Prime
Rep 2014; 6:96.
36. O’Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl
Compr Canc Netw 2012; 10:984-1021.
Supplemental Table 1 Treatment Patterns of Patients Treated for Other Conditions (Including Pre-Leukemic Conditions) Before Their
First Acute Myeloid Leukemia Diagnosis (n [ 81)
Treatmenta n
Hypomethylating agents 65
Azacitidine 26
Azacitidine and dexamethasone 14
Azacitidine and bevacizumab 1
Decitabine and dexamethasone 15
Decitabine 8
Decitabine and rituximab 1
Others 16
Cyclophosphamide and ﬂudarabine 1
Cyclophosphamide and rituximab 1
Cytarabine and decitabine 2
Cytarabine, daunorubicin and, dexamethasone 1
Cytarabine and idarubicin 1
Dexamethasone and docetaxel 2
Dexamethasone 1
Dexamethasone, bevacizumab, and paclitaxel 1
Dexamethasone and bortezomib 1
Dexamethasone, carboplatin, and docetaxel 1
Dexamethasone, cyclophosphamide, and doxorubicin 1
Dexamethasone, cyclophosphamide, doxorubicin, rituximab, and vincristine 1
Dexamethasone, cyclophosphamide, and vincristine 1
Dexamethasone, doxorubicin, and vincristine 1
Total 81
aTreatment regimens were identiﬁed based on the medication received during the ﬁrst 28 days after the initiation of the treatment.
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Supplemental Table 2 Patients With Acute Myeloid Leukemia Who Received Treatment Other Than Standard, Intermediate, or
Low-Intensity Therapy per the National Comprehensive Cancer Network Guidelines (n [ 136)
Treatmenta n
High-dose cytarabine (>500 mg/m2) 37
Cytarabine 28
Cytarabine and idarubicin 6
Cytarabine and cladribine 1
Cytarabine, etoposide, and mitoxantrone 1
Cytarabine and gemtuzumab 1
Other intermediate-dose therapyb 10
Cytarabine 100 mg/m2/d for 5 d, idarubicin 12 mg/m2/d for 2 d 3
Cytarabine 4
Cytarabine 100 mg/m2/d for 5 d, daunorubicin for 2 d 2
Cytarabine, etoposide, and mitoxantrone 1
Low-intensity therapy in combination therapy 13
Azacitidine and decitabine 3
Azacitidine and gemtuzumab 2
Cytarabine and arsenic trioxide 2
Azacitidine and daunorubicin 1
Azacitidine and methotrexate 1
Azacitidine and rituximab 1
Cytarabine, arsenic trioxide, and methotrexate 1
Cytarabine, decitabine, etoposide, and mitoxantrone 1
Decitabine and rasburicase 1
Other treatments 76
Dexamethasone 32
Arsenic trioxide 18
Arsenic trioxide and dexamethasone 4
Daunorubicin 4
Idarubicin 3
Arsenic trioxide and daunorubicin 2
Methotrexate 2
Mitoxantrone 2
Arsenic trioxide and epirubicin 1
Bortezomib 1
Cyclophosphamide, dexamethasone, and vincristine 1
Cyclophosphamide, doxorubicin, rituximab, and vincristine 1
Dexamethasone and docetaxel 1
Dexamethasone and sorafenib 1
Doxorubicin 1
Etoposide and mitoxantrone 1
Idarubicin and mitoxantrone 1
Total 136
aTreatment regimens were identiﬁed based on the medication received during the ﬁrst 28 days after the initiation of the treatment.
bPatients receiving these treatments were excluded from the main analysis because the regimen was not Ara-C 7 þ 3.
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Supplemental Table 3 Use of Transfusions and Supportive Therapies
Low-Intensity Therapy,
n [ 425
BSC With HU,
n [ 36
BSC Without HU,
n [ 455
Transfusions
Patients with  1 transfusion during the ﬁrst year following index date, n (%)
Any transfusiona 92 (22) 6 (17) 48 (11)
Platelet transfusion 46 (11) 5 (14) 28 (6)
RBC transfusion 24 (6) 0 9 (2)
Transfusion of unknown type 53 (12) 4 (11) 27 (6)
Number of transfusions per patient per month during the ﬁrst year following
index date among patients receiving transfusions, mean  SD
Any transfusion 0.6  0.6 0.4  0.5 0.8  0.9
Platelet transfusion 0.5  0.4 0.2  0.1 0.6  0.5
RBC transfusion 0.3  0.3 0.0  0.0 0.6  0.5
Transfusion of unknown type 0.6  0.6 0.6  0.5 0.6  0.5
Number of transfusions per patient per month between the ﬁrst and the
last transfusion observed among patients receiving transfusions, mean  SDb
Any transfusion 3.6  5.0 8.2  4.3 6.8  10.7
Platelet transfusion 3.5  2.6 5.4  2.7 9.1  13.0
RBC transfusion 4.5  7.4 0.0  0.0 2.8  2.0
Transfusion of unknown type 3.3  4.8 6.1  4.5 3.6  4.8
Duration of transfusion (mo), mean  SDc
Any transfusion 4.1  3.7 1.1  1.6 3.5  3.6
Platelet transfusion 2.7  2.8 0.6  0.4 2.4  2.9
RBC transfusion 3.3  4.0 0.0  0.0 5.0  5.4
Transfusion of unknown type 4.1  3.8 1.1  1.8 3.5  3.6
Patients with  1 bleeding event, n (%) 10 (2) 1 (3) 9 (2)
Supportive care
HU, n (%) 46 (11) 36 (100) 0
G(M)-CSF, n (%) 173 (41) 4 (11) 44 (10)
Filgrastim 94 (22) 2 (6) 36 (8)
Pegﬁlgrastim 98 (23) 2 (6) 9 (2)
Sargramostim 24 (6) 0 3 (<1)
Azole antifungals, n (%)d 134 (32) 10 (28) 103 (23)
Erythropoiesis-stimulating agents, n (%) 103 (24) 1 (3) 25 (5)
Epoetin alfa 72 (17) 1 (3) 15 (3)
Darbepoetin alfa 42 (10) 0 10 (2)
Pain medication, n (%) 334 (79) 23 (64) 263 (58)
NSAIDs 184 (43) 15 (42) 187 (41)
Morphine 116 (27) 7 (19) 84 (18)
Coanalgesics 283 (67) 16 (44) 152 (33)
Abbreviations: BSC ¼ best supportive care; G(M)-CSF ¼ granulocyte/granulocyte-macrophage colony-stimulating factor; HU ¼ hydroxyurea; NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs;
RBC ¼ red blood cell.
aAny transfusion included platelet transfusions, RBC transfusions and transfusions of unknown type.
bEvaluated during the ﬁrst year following index date.
cBased on patients with at least 2 transfusions on different dates; 19 (21%) of the 98 patients with any transfusion had only 1 transfusion.
dFor example, voriconazole, ﬂuconazole.
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